Aims An algorithm for non‐invasive diagnosis of amyloid transthyretin cardiac amyloidosis
(ATTR‐CA) and novel disease‐modifying therapies have prompted an active search for CA …

Over the last year, 5 national or international scientific societies have issued documents
regarding cardiac amyloidosis (CA) to highlight the emerging clinical science, raise …

Cardiac amyloidosis (CA) is now recognized as an important cause of heart failure.
Increased wall thickness and diastolic dysfunction of the left ventricle are the most easily …

Amyloidosis is a pathologic and clinical condition resulting from the accumulation of
insoluble aggregates of misfolded proteins in tissues. Extracellular deposition of amyloid …

Restrictive cardiomyopathy (RCM) is a heterogeneous group of diseases characterized by
restrictive left ventricular pathophysiology, ie a rapid rise in ventricular pressure with only …

The advent of newly available medical therapies for heart failure with reduced ejection
fraction (HFrEF) has resulted in many potential therapeutic combinations, increasing …

Cardiac amyloidosis is a restrictive cardiomyopathy determined by the accumulation of
amyloid, which is represented by misfolded protein fragments in the cardiac extracellular …

In heart failure with reduced ejection fraction (HFrEF), diminished tonic and reflex vagal
heart rate modulation and exaggerated sympathetic outflow and neural norepinephrine …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that
requires early diagnosis, management, and specific treatment. The availability of new …

Endomyocardial biopsy (EMB) is an invaluable and underused diagnostic tool for
myocardial disease. The primary indications are surveillance of cardiac allograft rejection …